We specifically explore key advancements in CKD diagnostics, focusing on emerging biomarkers—including neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), soluble urokinase plasminogen activator receptor (suPAR), and cystatin C—and their clinical applications. Here, PLAUR is linked to chronic kidney disease.